About imlifidase
IgG-cleaving enzyme
Used for
- Reduces donor-specific antibodies before kidney transplantation in highly sensitized adults.
Usual adult dose
One intravenous infusion, 0.25 mg/kg, usually within 24 hours before transplantation. A second dose may be considered after 24 hours.
Common side effects
- Infusion reactions
- Infections
- Pneumonia
- Nausea
Important warnings
- For use only in specialist transplant settings.
- Antibodies can rebound after treatment, risking rejection.
- May interfere with some antibody-based blood tests.
- Monitor closely for infection and infusion reactions.
Pregnancy
Not recommended during pregnancy; human pregnancy data are limited.
Breastfeeding
Unknown whether it passes into breast milk; breastfeeding is generally avoided during treatment.
Interactions
- May reduce the effectiveness of medicines containing immunoglobulins, including some antibody treatments.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.